Biosimilars
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Track global biosimilar approvals, market entry strategies, and regulatory pathways. Gain critical intelligence for your pharmaceutical BD and investment decisions.
Showing 1–12 of 27 articles
Quick answer
NovaPharmaNews Biosimilars hub for FDA covers 27 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Biosimilars Drive Significant Reductions in Specialty Drug Spending
FDA Draft Guidance Slashes Biosimilar PK Study Costs, Accelerating Market Entry
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Enters Diabetes Market
Biosimilars Growth in Brazil: Market Potential Post-ANVISA Regulatory Updates
Teva Reports Strong Q1 2026 Results as PONLIMSI Biosimilar Receives FDA Approval and Olanzapine LAI Advances
Teva's PONLIMSI Biosimilar Receives FDA Approval for All Prolia Indications as Q1 2026 Results Show Strong Growth
Biosimilars Market Analysis: US Landscape Post-Inflation Reduction Act 2026
Saudi Arabian Pharmaceutical Market: Impact of SFDA Expedited Drug Approvals
Rise of Biosimilars in US: FDA Approval Trends & Market Impact
Biosimilars Market Analysis: Impact of Recent FDA Approvals on US Pricing & Competition
FDA Biosimilar Approval Pathway: Key Regulatory Changes & Market Impact 2026
Sun Pharma Acquires Organon for $11.75 Billion in Major Pharmaceutical Merger
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.